RecruitingCOPD

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Eligible age

30+ yrs

Accepts

All genders

Locations

14 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.

Sponsor: Temple University

You may not qualify if…

✕ An individual who meets any of the following criteria will be excluded from participation in this study:
✕ 1. Current self-reported chronic use of positive airway pressure (PAP) therapy; continuous positive airway pressure (CPAP), or non-invasive positive pressure ventilation (NPPV)
✕ 2. A STOPBang Questionnaire score \> 5\*
✕ 3. Pregnancy or lactation
✕ 4. Treatment with another investigational drug or other intervention within the previous 30 days
✕ 5. Life expectancy less than 12 months due to COPD or other comorbid condition.
✕ 6. Recent upper airway surgery (within the previous month)
✕ 7. Recent head or neck trauma (within the previous month)